RAD Archives - Page 5 of 8 - Blue Horseshoe Stocks

Blue Horseshoe Stocks: ESPR Options, MVIS Recaps & More

Esperion Therapeutics, Inc. ESPR

ESPR found new highs once again yesterday for the second straight session after we initially tagged it for options trading potential on Tuesday.

In addition to monitoring Weekly In-the-money Calls, which yielded up the opportunity at gains ranging from 400-1400% on Tuesday, and continued their own runs yesterday, we also had specified a longer-term idea that continued to work extraordinarily well.

That idea, the 04/17 $90 Calls, traded from a low of 11.60 all the way up to 21.90 yesterday. It represented an excellent single-session intraday increase of 89%, and a whopping 525% jump over our observed low from Tuesday (3.50).

Big congratulations go out to any of our readers who reaped the benefits ESPR, which has easily emerged as our top target of the week! The stock is gapping up in the premarket this morning, so it appears as if we could see a further extension of those gains.

Microvision, Inc. MVIS

On Monday we tagged MVIS in a gap-up watchlist, and it has found its way into every one of our reports this week, setting new highs each day.

Yesterday the stock traded in a range from 3.42-4.23, a healthy intraday move of 24% From our observed low of 2.88 on Monday, that high marked a rise of 47% overall.

As you can see below, given the extremely over-bought look of the chart, now might be a good time to lock in any profits gained over the course of the week. This major move has been fueled by a PR out Monday in which the company announced orders totaling more than $14M it had received for components of its patented PicoP® display technology >> VIEW PR

Side Note:

Yesterday in advance of the FOMC Meeting, we cautioned readers to stay alert and watch for the effect that Janet Yellen’s commentary would have on the markets. To take advantage of this expected surge in either direction, we mentioned trading options calls on either the SPY, if the markets went up, or UVXY and/or VIX if they slid back. Either way it played out, we said, we wanted “to stay in-the-money with our strike prices.”

As it turned out, the Fed announcement caused a sharp rise in the markets, and as a result the SPY Calls were the ones to play. We saw substantial gains on in-the-money Calls as the SPY spiked to $211.27.

For example, the SPY $209.50 Calls traded in a range from .80-2.00, for an intraday move totaling 150% $210 Calls also spiked heavily from a low of .40 to as much as 1.59, a huge 297% jump.

Extended Watchlist:
FOLD, RAD, NQ, CNDO, SYN, SMLR

Blue Horseshoe Stocks: BCLI Recap & More

BrainStorm Cell Therapeutics, Inc. BCLI

2015 is upon us and our first order of business is to address one of the stocks we tagged in Wednesday’s premarket report. BCLI had a strong session, as it pushed its way up from an early low of 4.02 to an aftyernoon high of 4.94; a solid +23% performance.

The strong session was apparently aided by the pre-emptive PR the company released which served as a reminder that results from Phase 2a trials of its ALS (Lou Gehrig’s Disease) treatment would be released on Monday. This morning the stock is gapping up wildly as anticipation grows, having already hit a premarket high of 7.28, which represents a total increase of 81% over the low we observed on New Year’s Eve.

Monday’s data release, which is expected to be positive, should most likely produce one of two effects. Either the results will beat expectations and facilitate another strong move, or they will fail to meet the mark and cause a pullback. In case of the latter, there may be rebound opportunities waiting just around the corner.

RedHill BioPharma Ltd. RDHL & NephroGenex, Inc. NRX

We also had this pair of standouts appear in Wednesday’s report, with each stock making a similar move. Both started the day with significant spikes in PPS, followed by a tapering off into the close.

RDHL made a sensational jump beginning almost immediately at the open running from 12.52 on up to 17.85 before its pullback, an intraday spike equaling 42.5%. Coincidentally, the stock ended the session having traded 42.5X its 3-month average volume.

NRX saw an initial low of 12.96, followed by a healthy 39% run to a high of 17.98. This play would offer one more opportunity in the form of an intraday swing as it came down and rebounded off of the 12.60-mark before returning to 15.15, an added 20% move, bringing the day’s cumulative total of possible gains to 59% .

Extended Watchlist:
CUR, ARWR, CLF, MSTX, RAD

Blue Horseshoe Stocks: NQ, RAD Reviews & More

NQ Mobile, Inc. NQ

NQ appeared at the top of our extended watchlist yesterday and stood out as the day’s top pick. The stock increased gradually all day long from an early low of 3.86, and touched 4.77 just prior to the closing bell. That solid intraday move was good for gains of up to 24% as NQ traded close to 6X its 3-month average volume.

The spike came on the heels of a big announcement from the company as it gears up for an $80M buyback program that will last for the duration of 2015.

BEIJING and DALLAS, Dec. 23, 2014 /PRNewswire/ – NQ Mobile, Inc. (“NQ Mobile” or the “Company“) (NQ), a leading global provider of mobile internet services, announced today that its Board of Directors has authorized a share repurchase program under which the Company may repurchase up to US$80 million of its shares over the next 12 months. >> FULL PR

Rite-Aid Corp. RAD

Just a reminder for those who might have missed our close coverage of RAD over the past week, we latched onto this stock last Tuesday, catching it at a low of 5.79. We’ve seen incremental gains from this play from that time, and yesterday it continued to press upward, setting a new high at 7.45. That marked an overall increase of 29% that we’ve observed in just one week.

The stock continues to push its way up in premarket trading this morning, having traded as high as 7.54 so far, so we’ll be certain to pay close attention as we close out the early portion of this split trading week, and once we return on Friday.

As we stated yesterday, according to the opinions of many analysts, RAD has room to see a PPS in the $8-range, and with the movements we’ve tracked over a short period of time we wouldn’t be at all surprised to see that happen.

The markets wrap up at 1PM this afternoon for the start of the holiday break. We want to take this opportunity to extend our warmest Season’s Greetings to all of our readers regardless of how you will be spending the hiatus. Be safe and well, and we will be back bright and early on Friday to close out the week! Cheers!

Extended Watchlist:
ISNS, DRD, HALO, WATT, LIQD(Gap-Down, Watching for Bottom)

Blue Horseshoe Stocks: RAD, ACHN Recaps & More

Achillon Pharmaceuticals, Inc. ACHN

ACHN stood out amongst the stocks we discussed in yesterday’s morning report. The move came in conjunction with the announcement that the company’s Hep C treatment currently in trials had successfully cured all of the patients in the latest clinical test.

As a result ACHN ran from a morning low of 14.56 on up to 16.87 for a solid 16% intraday move, on its highest volume traded since June.

We’ve been tracking ACHN for over a month now, and in that time have observed a low of 12.00 (Nov. 12th). As of yesterday’s high, that represents an overall increase of 40% in a relatively short amount of time.

Rite-Aid Corp. RAD

We began paying attention to RAD on Tuesday of last week, and the stock has made some good progress since then. Yesterday was no exception, with RAD adding another 6% to the healthy upward movements we’ve already witnessed.

From the low of 5.79 we observed last Tuesday after adding it to our watchlist for the first time, to yesterday’s high of 7.19, equates to a move of 25% in a span of just five sessions. That’s more than enough to hold our attention as we head into the New Year.

It’s worth mentioning that the Cowen Group investment research arm upgraded RAD from a ‘Neutral’ to an ‘Outperform’ rating, with a price target of 8.50/share, and one of our favorite sites, BARCHART.com is currently rating RAD a 100% Short-Term ‘Buy’, with an 88% ‘Buy’ Rating overall.

Extended Watchlist:
NQ, ARIA, ALSK, CYTK, ICLD, DRYS

Blue Horseshoe Stocks: TRXC Recap & Much More

TransEnterix Inc. TRXC

TRXC stood out among the other mentions in Friday’s premarket report. Following our tag of this stock it shot quite rapidly from an early low of 2.73, and reached a subsequent high of 4.05 shortly after 11AM EST.

We want to congratulate any of our reader who were able to take advantage of that timely alert which yielded the opportunity at intraday gains of up to 48% The healthy spike came on nearly tenfold the 3-month average trading volume.

Friday’s move came in conjunction with the announcement of successful pre-clinical trials for its SurgiBot minimally invasive surgery system. Two different doctors used TRXC’s product in actual medical procedures and subsequently offered their endorsements. It is an important step on the way to FDA application submission, which the company has stated should be on the table by mid-2015. Thus, TRXC may be one that we’ll want to have on a more long-term watch.

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is pioneering the use of robotics and flexible instruments to improve minimally invasive surgery, today announced the successful completion of four general surgery and urology procedures using its SurgiBot system patient-side robotic surgery system. >> FULL PR

The First Marblehead Corp. FMD

We also wanted to give a quick nod to FMD for a solid performance following its inclusion in Friday morning’s watchlist. The stock found a low of 4.65 within the first several minutes of the open, and would go on to end the day with a on a high note, reaching as high as 5.35 and marking a respectable intraday move of 15%

Nuvilex, Inc. NVLX

Our first mention of NVLX dates all way back to August of 2013 when we released a special report on the company and its pancreatic cancer treatment, which at the time was in the early stages of Phase-2 trials. (Read the Special Report HERE)

A major development hit the presswires this morning regarding the FDA’s granting of ‘Orphan Drug’ status to that treatment, so we wanted to bring the stock back into the mix.

It’s coming off of a recent bottom as well, so NVLX is certainly going to be reserved a spot on our watchlist as the story continues to play out. The company has stated that Phase-3 trials should begin in 2015.

SILVER SPRING, Md., Dec. 22, 2014 (GLOBE NEWSWIRE) — Nuvilex, Inc. (NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Nuvilex orphan drug designation for its pancreatic cancer treatment. >> FULL PR

Rite-Aid Corp. RAD

We tagged RAD for tracking this past Tuesday, and the stock responded with a respectable performance on the week. An earnings beat as well as heightened guidance facilitated a healthy move from a low of 5.73 to a subsequent high of 7.05, marking a 23% intraweek spike.

Extended Watchlist:
GSS(Bottom Bouncer coming off 52-week lows), CANF, APP, TGE, ACHN